NASDAQ Affirms Trading Halt on KaloBios Pharma (KBIO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Nasdaq Halts KaloBios Pharmaceuticals, Inc.
December 17, 2015 10:41 AM ESTNEW YORK, Dec. 17, 2015 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) at 06:48:07 Eastern Time for "additional information requested" from the company at a last price of $23.59.
... More